CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback